Continuous Glucose Monitoring for Diabetes Management in Dementia
What You Need to Know Before You Apply
What is the purpose of this trial?
Aim 1: Characterize shared decision-making and unmet patient-caregiver dyads needs for patients with diabetes and Alzheimer's Disease and related dementias (ADRD) while using a continuous glucose monitoring (CGM) device.Aim 2: Develop an interactive tool to enhance shared decision-making for diabetes management.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must have active prescriptions for diabetes. You cannot participate if you use an automated insulin delivery system or take ascorbic acid during the monitoring period.
Is continuous glucose monitoring safe for humans?
How is continuous glucose monitoring different from other treatments for diabetes management in dementia?
Continuous glucose monitoring (CGM) is unique because it provides real-time glucose level data, helping to manage diabetes more effectively by reducing the frequency and severity of low blood sugar episodes. Unlike traditional methods, CGM offers continuous insights into glucose trends, which can be particularly beneficial for individuals with dementia who may have difficulty managing their diabetes.26789
What data supports the effectiveness of continuous glucose monitoring for diabetes management in dementia?
Research shows that continuous glucose monitoring (CGM), including flash glucose monitoring, helps people with diabetes by providing real-time data that can improve blood sugar control. This technology has been linked to more time spent in the target blood sugar range and less time in high or low blood sugar levels, which can be beneficial for managing diabetes in people with dementia.234510
Who Is on the Research Team?
April Savoy, PhD
Principal Investigator
Indiana University School of Medicine
Are You a Good Fit for This Trial?
This trial is for people with both diabetes and Alzheimer's or related dementias who have not used a continuous glucose monitoring device before. They need to be under the care of certain healthcare professionals, have internet access, speak English, and live in the community with a caregiver who interacts with them daily.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline and CGM Training
Patient-caregiver dyads participate in a semi-structured interview to establish a baseline and receive CGM training and instructions for device use.
CGM Monitoring
Participants wear the CGM device for 14 days with follow-up interviews and a debrief interview for assessment and technical support.
User-Centered Design Session
Patient-caregiver dyads and clinicians participate in a user-centered design session to guide the design of interactive information displays.
Follow-up
Participants are monitored for safety and effectiveness after the intervention.
What Are the Treatments Tested in This Trial?
Interventions
- Continuous Glucose Monitoring
- Interactive Tool
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator